Cat. No.: HY-P99275

Biologically Validated

Patritumab

Name: Patritumab
Brand: MedChemExpress
SKU: HY-P99275
Price: 390.00 USD
Availability: InStock
Rating: 5 (2 reviews)

(Synonyms: AMG 888; U3-1287)

2 Cited Publications

고객리뷰

Based on 2 publication(s) in Google Scholar

Patritumab (AMG 888; U3-1287) is a neutralizing antibody targeting HER3 (ErbB3) that binds to the extracellular domain and induces HER3 internalization. Patritumab prevents heregulin binding, downregulates cell surface HER3, and blocks ligand-induced HER3 phosphorylation and downstream PI3K/AKT signaling. Patritumab in combination with dual HER2 blockade enhances apoptosis and growth inhibition in HER2-overexpressing breast cancer cells, and enhances antitumor effects in xenograft tumors. Patritumab can be used for research on breast cancer.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Purity : 99.28%
CAS No.: 1262787-83-6
분자량:146.86 kDa

보관:

Shipping with dry ice

Please store the product under the recommended conditions in the Certificate of Analysis.

Patritumab Chemical Structure

CAS No.: 1262787-83-6

사이즈

가격

재고

수량

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Antibody-Drug Conjugates

One-stop solution for XDC (ADC/PDC/RDC/ApDC/FDC/ISAC/VDC/SMDC)

Biological Activity
- 제품 설명
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vitro
- In Vivo
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Format
- 신청
- Verified Bioactivity
Chemical Information
Publications (2)
순도&문서
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

Isotype

Human IgG1(K214R) kappa

Recommend Isotype Controls

Human IgG1 (K214R) kappa, Isotype Control

Species Reactivity

Human

IC₅₀ & Target

^[1]^[2]^[3]^[4]^[5]

HER3

HER2

PI3K

Akt

All EGFR Isoforms :

All Akt Isoforms :

All PI3K Isoforms :

In Vitro

Anti-cancerApoptosisOthers

Anti-cancer

Patritumab (500 nM) competes with Biotin (HY-B0511)-labeled Patritumab for HER3 binding sites on MDA-MB-453 cells in a concentration-dependent manner^[1].
Patritumab (10 μg/mL) significantly inhibits MCF7 breast cancer cell viability only in the presence of Erlotinib (HY-50896)^[2].
Patritumab (100 μg/mL; 120 h), in triple combination with Trastuzumab (HY-P9907) and Pertuzumab (HY-P9912), potently reduces the viability of SKBR3-HRG and BT474-HRG cells even at the lowest Trastuzumab concentration^[4].
Patritumab (50 μg/mL; 120 h) combined with Pertuzumab and Trastuzumab reverses heregulin-induced drug resistance in the BT-474, MDA-MB-453, and HCC1419 paracrine models^[4].
Patritumab (120 h) in combination with Pertuzumab synergistically inhibits the viability of SKBR3-HRG and BT474-HRG cells, with median-effect CI values of 0.11 and 0.13, respectively^[4].
Patritumab (120 h) combined with Pertuzumab reduces cell viability in BT-474, MDA-MB-453, and HCC1419 paracrine heregulin models^[4].
Patritumab (U3-1287) (20 μg/mL; 0-48 h) downregulates HER3 protein from 1 h to 48 h in BT474, SKBR3, and MDA453 cells^[5].
Patritumab (20 μg/mL; 24 h) blocks HER2 inhibitor-induced cell surface HER3 upregulation and reduces cell surface HER3 levels in BT474, SKBR3, and MDA453 cells^[5].
Patritumab (20 μg/mL; 24 h) enhances the inhibition of HER3 and AKT signaling pathways when HER2 blockade is added in BT474, SKBR3, and MDA453 cells^[5].
Patritumab (20 μg/mL; every 2-3 days) reduces the 2D growth of BT474, SKBR3, and MDA453 cells when combined with Lapatinib plus Trastuzumab^[5].
Patritumab (20 μg/mL; 12-16 days) reduces 3D Matrigel colony formation in BT474, SKBR3, and MDA453 cells when combined with Lapatinib plus Trastuzumab^[5].
Patritumab (20 μg/mL; 24 h) reduces HER3 and AKT signaling in HR6 cells when combined with Lapatinib plus Trastuzumab^[5].

Anti-cancer

Apoptosis

Patritumab (20 μg/mL; 48 h) alone does not induce apoptosis, but the addition of Lapatinib (HY-50898) combined with Trastuzumab increases apoptosis in BT474, SKBR3, and MDA453 cells^[5].

Others

Patritumab (10 μg/mL) binds to HEK293 cells expressing HER3-GFP, and this binding is significantly inhibited by Ab1, whereas other anti-HER3 rat monoclonal antibodies do not inhibit it^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[4]

Cell Line:

HER2-positive breast cancer SKBR3-HRG and BT474-HRG cells
Concentration:

100 μg/mL
Incubation Time:

120 h
Result:

Triple combination with Trastuzumab and Pertuzumab drastically decreased viable cell counts even at the lowest Trastuzumab concentration in both SKBR3-HRG and BT474-HRG cells.

Cell Viability Assay^[4]

Cell Line:

BT-474, MDA-MB-453, and HCC1419 HER2-positive breast cancer cells
Concentration:

50 μg/mL
Incubation Time:

120 h
Result:

BT-474, MDA-MB-453, and HCC1419 cells developed resistance to Trastuzumab in the presence of heregulin.
Adding Pertuzumab to Trastuzumab reversed this resistance in these paracrine models.

Western Blot Analysis^[5]

Cell Line:

BT474, SKBR3, and MDA453 cells
Concentration:

20 μg/mL
Incubation Time:

1, 4, 14, 24, and 48 h
Result:

HER3 protein showed a modest decrease starting at 1 h and lasting through 48 h in BT474, SKBR3, and MDA453 cells.

Western Blot Analysis^[5]

Cell Line:

BT474, SKBR3, and MDA453 cells
Concentration:

20 μg/mL
Incubation Time:

24 h
Result:

Dual HER2 inhibition increased cell-surface HER3 in all three cell lines.
Addition to dual HER2 inhibition blocked this increase and almost completely downregulated cell-surface HER3 levels.

Apoptosis Analysis^[5]

Cell Line:

BT474, SKBR3, and MDA453 cells
Concentration:

20 μg/mL
Incubation Time:

48 h
Result:

Did not induce apoptosis alone.
Addition to Lapatinib plus Trastuzumab resulted in a clear increase in apoptosis in all cell lines.

Western Blot Analysis^[5]

Cell Line:

BT474, SKBR3, and MDA453 cells
Concentration:

20 μg/mL
Incubation Time:

24 h
Result:

p-HER3 was lower in cells with the triple combination.
Enhanced inhibition of S473 p-Akt in SKBR3 and MDA453 cells.
T308 p-Akt was lower in BT474 and SKBR3 cells with all three inhibitors than with other conditions.

Western Blot Analysis^[5]

Cell Line:

HR6 cells
Concentration:

20 μg/mL
Incubation Time:

24 h
Result:

Addition to lapatinib plus trastuzumab reduced p-HER3, total HER3, and S473 p-Akt levels.

In Vivo

Anti-cancer

Patritumab (100 µg/mouse; intraperitoneal injection; administered twice on day 0 and day 7) inhibits the growth of BT474 breast cancer xenografts in nude mice^[2].
Patritumab (25 mg/kg; intraperitoneal injection; once weekly; for 3 weeks) combined with Trastuzumab (10 mg/kg) partially inhibits the growth of BT474-HRG xenograft tumors^[4].
Patritumab (25 mg/kg; intraperitoneal injection; once weekly; for 3 weeks) combined with Pertuzumab (25 mg/kg) inhibits BT474-HRG tumor growth, induces tumor regression, and suppresses HER3 in vivo^[4].
Patritumab (25 mg/kg; intraperitoneal injection; once weekly; for 3 weeks) combined with Pertuzumab (25 mg/kg) and Trastuzumab (10 mg/kg) produces the strongest anti-tumor effect against BT474-HRG, including complete clearance of three out of seven tumors, and inhibits HER3 in vivo^[4].
Patritumab (25 mg/kg; intraperitoneal injection; once weekly; for 3 weeks) combined with Pertuzumab (25 mg/kg) and Trastuzumab (10 mg/kg) produces maximal tumor regression in JIMT-1 xenograft tumors^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

KSN nude (male, 6 weeks of age at purchase)^[2]
Dosage:

100 µg/mouse
Administration:

i.p.; twice on days 0 and 7
Result:

In BT474 xenograft-bearing nude mice, tumor growth was significantly inhibited compared with isotype control.

Animal Model:

BALB/cAJcl-nu/nu athymic nude (female, 7 weeks old)^[4]
Dosage:

25 mg/kg
Administration:

i.p.; once weekly; 3 weeks
Result:

The Trastuzumab-containing double combination partially prevented BT474-HRG tumor growth in vivo.

Animal Model:

BALB/cAJcl-nu/nu athymic nude (female, 7 weeks old)^[4]
Dosage:

25 mg/kg
Administration:

i.p.; once weekly; 3 weeks
Result:

The Pertuzumab-containing double combination significantly prevented BT474-HRG tumor growth and mediated tumor regression compared with vehicle.
In vivo HER3 immunoblot PD showed suppressed HER3 expression in the Pertuzumab-containing double-combination arm relative to control.

Animal Model:

BALB/cAJcl-nu/nu athymic nude (female, 7 weeks old)^[4]
Dosage:

25 mg/kg
Administration:

i.p.; once weekly; 3 weeks
Result:

Triple combination significantly prevented BT474-HRG tumor growth and mediated tumor regression compared with vehicle; three of seven tumors were completely eradicated.
In vivo HER3 immunoblot PD showed suppressed HER3 expression in the triple-combination arm relative to control.

Animal Model:

BALB/cAJcl-nu/nu athymic nude (female, 7 weeks old)^[4]
Dosage:

25 mg/kg
Administration:

i.p.; once weekly; 3 weeks
Result:

Triple combination induced significant tumor regression in JIMT-1 xenografts compared with controls and produced the maximum antitumor effect among the regimens.

Related Protocols :

Gene ID

2065 [NCBI]

Accession

P21860

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Format

Human IgG1 kappa

신청

ELISA, FACS, Functional assay

Verified Bioactivity

Flow cytometric analysis of 1×10⁶ MCF-7 cells labelling HER3 (red) with Patritumab (HY-P99275). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1(K214R) kappa Isotype Control (HY-P99995, blue) was used as the isotype control.
Immobilized Human HER3/ERBB3 Protein (ECD, His Tag) can bind Patritumab. The EC₅₀ for this effect is 1.41 ng/mL.
Loaded Patritumab on AHC2 biosensor, can bind HER3 Protein, Human (HEK293, His, HY-P72625) with an affinity constant of 1.804E-09 M as determined in BLI assay.

Chemical Information

CAS No. 1262787-83-6
Appearance Liquid
분자량 146.86 kDa
Color Colorless to light yellow
SMILES

[Patritumab]
Synonyms

AMG 888; U3-1287
선적

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
보관

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (2)

All WB

Sort by:

Journal Impact Factor

Clin Cancer Res

ERBB3 overexpression is enriched in diverse patient populations with castration-sensitive prostate cancer and is associated with a unique AR activity signature. [Abstract]

2024 Apr 15;30(8):1530-1543. PMID: 38306015

Patritumab purchased from MedChemExpress. Usage Cited in: Clin Cancer Res. 2024 Apr 15;30(8):1530-1543. [Abstract]

Patritumab (10 μM; 2 h) reduced pHER3 after NRG1 stimulation (100 ng/mL; 15 min) in CWR-R1 cells.
bioRxiv

2026 Jun 19.

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (292 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Inhibitory Antibodies User Guide (603 KB)

References

[1]. Li X, et al. DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors. Journal of translational medicine. 2024 Apr 17;22(1):362. [Content Brief]

[2]. Okita K, et al. Novel functional anti-HER3 monoclonal antibodies with potent anti-cancer effects on various human epithelial cancers. Oncotarget. 2020 Jan 07;11(1):31-45.

[3]. Wang Y, et al. A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC. Cellular oncology (Dordrecht, Netherlands). 2026 Jan 27;49(1):31.

[4]. Watanabe S, et al. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer. Cancer Med. 2019 Mar;8(3):1258-1268.

[5]. Garrett JT, et al. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Feb 01;19(3):610-9.

Calculators

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Patritumab

2 Cited Publications

100 mg 견적 받기

Subscribe to the

MedChemExpress

Newsletter

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

Patritumab

Publications Citing Use of MedChemExpress (MCE) Patritumab

All EGFR Isoforms

All Akt Isoforms

All PI3K Isoforms